Pacific Biosciences of California, Inc.
General ticker "PACB" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $518.1M (TTM average)
Pacific Biosciences of California, Inc. does not follow the US Stock Market performance with the rate: -0.2%.
Estimated limits based on current volatility of 9.5%: low 1.69$, high 1.98$
Factors to consider:
- Total employees count: 485 (-15.7%) as of 2025
- US accounted for 43.6% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Operational and conduct risks, Market competition, Manufacturing issues, Customer concentration, Leadership turnover
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.33$, 3.21$]
- 2026-12-31 to 2027-12-31 estimated range: [1.18$, 2.89$]
Financial Metrics affecting the PACB estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 21.38 > 2.08
- Positive: Shareholder equity ratio, % of 0.68 <= 7.04
- Positive: Inventory ratio change, % of 0.98 <= 1.34
- Positive: Interest expense per share per price, % of 1.29 <= 1.42
- Positive: -51.61 < Industry operating profit margin (median), % of -29.60
- Positive: Industry inventory ratio change (median), % of 0.70 <= 1.15
Short-term PACB quotes
Long-term PACB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $200.52MM | $154.01MM | $160.00MM |
| Operating Expenses | $534.99MM | $628.33MM | $713.87MM |
| Operating Income | $-334.47MM | $-474.31MM | $-553.86MM |
| Non-Operating Income | $16.31MM | $164.78MM | $7.80MM |
| Interest Expense | $14.34MM | $13.41MM | $6.95MM |
| R&D Expense | $187.17MM | $134.92MM | $97.31MM |
| Income(Loss) | $-318.16MM | $-309.54MM | $-546.06MM |
| Taxes | $-11.42MM | $0.32MM | $0.32MM |
| Net Income(Loss)* | $-306.74MM | $-309.85MM | $-546.38MM |
| Stockholders Equity | $701.30MM | $506.59MM | $5.35MM |
| Inventory | $56.68MM | $58.76MM | $49.28MM |
| Assets | $1,746.01MM | $1,260.45MM | $784.08MM |
| Operating Cash Flow | $-259.17MM | $-206.06MM | $-111.21MM |
| Capital expenditure | $8.84MM | $6.19MM | $2.71MM |
| Investing Cash Flow | $4.60MM | $124.00MM | $115.45MM |
| Financing Cash Flow | $108.89MM | $-42.99MM | $3.43MM |
| Earnings Per Share** | $-1.21 | $-1.13 | $-1.82 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.